Lo que se necesita saber | 21 SEP 20

Tratamiento farmacológico del dolor

Opciones apropiadas de analgésicos para el tratamiento del dolor, considerando su supuesto origen.
Autor/a: Kyung-Hoon Kim, Hyo-Jung Seo, Salahadin Abdi, and Billy Huh J Pain 2020;33(2):108-120.
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas


1. Merskey H, Albe Fessard D, Bonica JJ, Carmon A, Dubner R, Kerr FWL, et al. Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain 1979; 6: 249-52.

2. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 2003; 102: 1-8

 3. Baron R, Maier C, Attal N, Binder A, Bouhassira D, Cruccu G, et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain 2017; 158: 261-72.

4. Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain 2008; 138: 343-53.

5. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the neuropathic pain symptom inventory. Pain 2004; 108: 248-57.

6. Loeser JD, Treede RD. The Kyoto protocol of IASP basic pain terminology. Pain 2008; 137: 473-7.

7. Kallakuri S, Singh A, Chen C, Cavanaugh JM. Demonstration of substance P, calcitonin gene-related peptide, and protein gene product 9.5 containing nerve fibers in human cervical facet joint capsules. Spine (Phila Pa 1976) 2004; 29: 1182-6.

8. Park SC, Kim KH. Effect of adding cervical facet joint injections in a multimodal treatment program for long-standing cervical myofascial pain syndrome with referral pain patterns of cervical facet joint syndrome. J Anesth 2012; 26: 738- 45.

9. Kim TK, Kim KH, Kim CH, Shin SW, Kwon JY, Kim HK, et al. Percutaneous vertebroplasty and facet joint block. J Korean Med Sci 2005; 20: 1023-8.

10. Kim KH, Choi SH, Kim TK, Shin SW, Kim CH, Kim JI. Cervical facet joint injections in the neck and shoulder pain. J Korean Med Sci 2005; 20: 659-62.

11. Demondion X, Vidal C, Glaude E, Subocz L, Francke JP, Cotten A. The posterior lumbar ramus: CT-anatomic correlation and propositions of new sites of infiltration. AJNR Am J Neuroradiol 2005; 26: 706-10.

12. Danelich IM, Wright SS, Lose JM, Tefft BJ, Cicci JD, Reed BN. Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. Pharmacotherapy 2015; 35: 520-35.

13. Handin RI. The history of antithrombotic therapy: the Discovery of heparin, the vitamin K antagonists, and the utility of aspirin. Hematol Oncol Clin North Am 2016; 30: 987-93.

14. Smith DK, Demetriou T, Weber C. Aspirin for primary prevention: USPSTF recommendations for CVD and colorectal cancer. J Fam Pract 2019; 68: 146-51.

15. MacKintosh ML, Crosbie EJ. Prevention strategies in endometrial carcinoma. Curr Oncol Rep 2018; 20: 101.

16. Serrano D, Bonanni B, Brown K. Therapeutic cancer prevention: achievements and ongoing challenges - a focus on breast and colorectal cancer. Mol Oncol 2019; 13: 579-90.

17. Hurwitz LM, Joshu CE, Barber JR, Prizment AE, Vitolins MZ, Jones MR, et al. Aspirin and non-aspirin NSAID use and prostate cancer incidence, mortality, and case fatality in the atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev 2019; 28: 563-9.

18. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-8.

19. Botting RM. Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacol Rep 2010; 62: 518-25.

20. Tosco P, Lazzarato L. Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin. ChemMedChem 2009; 4: 939-45.

21. Lucido MJ, Orlando BJ, Vecchio AJ, Malkowski MG. Crystal structure of aspirin-acetylated human cyclooxygenase-2: insight into the formation of products with reversed stereochemistry. Biochemistry 2016; 55: 1226-38.

22. Chiang N, Serhan CN. Aspirin triggers formation of antiinflammatory mediators: new mechanism for an old drug. Discov Med 2004; 4: 470-5.

23. Brune K, Renner B, Tiegs G. Acetaminophen/paracetamol: a history of errors, failures and false decisions. Eur J Pain 2015; 19: 953-65.

24. Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology 2013; 21:201-32.

25. Candido KD, Perozo OJ, Knezevic NN. Pharmacology of acetaminophen, nonsteroidal antiinflammatory drugs, and steroid medications: implications for anesthesia or unique associated risks. Anesthesiol Clin 2017; 35: e145-62.

26. Schildknecht S, Daiber A, Ghisla S, Cohen RA, Bachschmid MM. Acetaminophen inhibits prostanoid synthesis by scavenging the PGHS-activator peroxynitrite. FASEB J 2008; 22: 215-24.

27. Aminoshariae A, Khan A. Acetaminophen: old drug, new issues.

J Endod 2015; 41: 588-93. 28. Smith HS. Potential analgesic mechanisms of acetaminophen. Pain Physician 2009; 12: 269-80.

29. Sasaki F, Yokomizo T. The leukotriene receptors as therapeutic targets of inflammatory diseases. Int Immunol 2019; 31: 607-15.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023